This study is in progress, not accepting new patients
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
a study on Alzheimer's Disease
Alzheimer Disease Antibodies, Monoclonal Crenezumab dose level 1 Crenezumab dose level 2 Crenezumb dose level 3 Optional OLE window: Crenezumab
Lead Scientist at UCSF
- Adam Boxer
Adam L. Boxer, MD, PhD is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Genentech, Inc.
- Phase 1
- Study Type
- Last Updated